Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial Therapy for High Blood Pressure.
Publication: Blood Weekly
Publication Date: 02-OCT-08
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
Daiichi Sankyo, Inc. announced the filing of a supplemental New Drug Application (sNDA) with the United States Food and Drug Administration (FDA) for the combination treatment AZOR(R) (amlodipine and olmesartan medoxomil) as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goal. AZOR is indicated for the treatment of hypertension, alone or with other antihypertensive agents. Presently, AZOR is...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
